Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently complicates the management of patients aged 75 and older, primarily due to the high prevalence of polypharmacy. Research indicates that this demographic often balances complex medication regimens for comorbidities like hypertension and type 2 diabetes alongside liver-directed therapies, necessitating rigorous medication reconciliation to avoid adverse drug events and potential drug-induced liver injury.
The Intersection of MASLD and Polypharmacy
Managing MASLD in the geriatric population requires a shift in clinical focus. According to the American Association for the Study of Liver Diseases (AASLD), MASLD is defined by evidence of hepatic steatosis in the presence of at least one cardiometabolic risk factor. For patients 75 and older, this condition rarely exists in isolation.
Data published in Clinical Gastroenterology and Hepatology highlight that older adults with MASLD are often prescribed five or more concurrent medications. This polypharmacy burden increases the risk of drug-drug interactions (DDIs) that can exacerbate liver inflammation or interfere with the metabolism of drugs used to treat metabolic syndrome. Clinicians must weigh the benefit of aggressive metabolic control against the risk of falls, hypoglycemia, and renal strain in patients with advanced age.
Risks of Medication Overload in Older Adults
The physiological changes associated with aging—such as reduced renal clearance and altered hepatic blood flow—significantly impact how drugs are processed. When a patient with MASLD is also managing chronic conditions, the risk of "prescribing cascades" increases.
- Drug-Induced Liver Injury (DILI): Certain medications commonly used in this age group, including specific statins or non-steroidal anti-inflammatory drugs (NSAIDs), require careful monitoring in patients with underlying liver steatosis.
- Adherence Challenges: Complex regimens often lead to lower medication adherence, which can worsen glycemic control and indirectly accelerate the progression of liver fibrosis.
- Metabolic Impact: Some medications required for psychiatric or cardiovascular health, such as certain antipsychotics or beta-blockers, may contribute to weight gain or insulin resistance, further complicating the clinical picture of MASLD.
Clinical Strategies for Medication Management
To mitigate these risks, medical guidelines from the European Association for the Study of the Liver (EASL) emphasize a personalized approach to care. Clinicians are encouraged to perform regular "deprescribing" audits to identify medications that are no longer clinically necessary or that offer minimal benefit compared to the risk of toxicity.
By prioritizing medications that address both metabolic health and liver safety, providers can reduce the pill burden. Lifestyle modifications, while essential, must be tailored to the patient’s functional status. In patients 75 or older, nutritional interventions should focus on preventing frailty and sarcopenia, rather than aggressive weight loss, which may be counterproductive in this specific age group.
Frequently Asked Questions
Why is polypharmacy a specific concern for MASLD patients?
MASLD is closely linked to metabolic syndrome. Patients often take multiple medications for blood pressure, cholesterol, and diabetes, which can interact with each other and increase the strain on the liver’s metabolic pathways.
How do clinicians identify medication risks in older adults?
Physicians utilize tools like the Beers Criteria, which lists medications that are potentially inappropriate for use in older adults, to identify drugs that may cause confusion, falls, or liver stress.
Can lifestyle changes still help patients over 75?
Yes. Even in older populations, dietary adjustments—such as reducing ultra-processed sugars and focusing on protein intake to maintain muscle mass—can improve liver health and metabolic markers without the risks associated with rapid weight loss.
Keep reading